Secukinumab is efficacious in clearing moderate-to-severe scalp psoriasis: 12 week results of a randomised phase IIIb study



Introduction: Secukinumab, an anti-IL17A monoclonal antibody, has been shown to be efficacious in the treatment of moderate-to-severe psoriasis and psoriatic arthritis. Here we report the primary objective of a phase 3b study of patients with moderate-to-severe scalp psoriasis, evaluating the superiority of secukinumab over placebo at Week 12 with respect to the proportion of patients achieving a Psoriasis Scalp Severity Index 90 (PSSI90) response rate.
Methods: 102 patients with moderate-to-severe scalp psoriasis were randomized 1:1 to secukinumab 300mg or placebo at baseline, weeks 1, 2, 3, and 4 and then every 4 weeks for 12 weeks. Moderate-to-severe scalp psoriasis was defined as a PSSI score ≥12, an Investigator’s Global Assessment modified 2011 (IGA mod 2011) scalp score ≥3, along with ≥30% of the scalp surface area affected. At Week 12, patients on placebo who did not achieve PSSI90 were switched in a blinded manner to secukinumab 300mg until study completion.
Results: The mean baseline PSSI score was 34.1 in the secukinumab 300mg group (n=51) and 33.9 in the placebo group (n=51). At Week 12, PSSI90 responses were achieved by a significantly greater percentage of patients receiving secukinumab 300mg (27/51 [52.9%]) than placebo (1/51 [2.0%]), (P<0.001). Additionally, IGA mod 2011 responses of 0/1 for the scalp at Week 12 were achieved by a significantly greater percentage of patients receiving secukinumab 300mg (29/51 [56.9%]) than placebo (3/51 [5.9%]), (P<0.001).
Conclusion: Secukinumab demonstrated a superior ability for clearing moderate-to-severe scalp psoriasis at 12 weeks than placebo. No new or unexpected safety signals were observed.


Mr Eric Mate